Mobile

An international study to assess the safety and efficacy of new investigational drugs and standard of care in patients with chronic hepatatis C virus infection

Update Il y a 4 ans
Reference: EUCTR2011-005055-14

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the efficacy of PSI-7977 in combination with RBV administered for 12 weeks compared with PEG/RBV administered for 24 weeks in treatment-naïve patients with HCV genotype 2 or 3 as assessed by the rate of SVR12 (HCV RNA <LOQ 12 weeks after cessation of therapy)

Inclusion criteria

  • Chronic Genotype 2 or 3 HCV Infection

Links